KR102703633B1 - 서브틸라제 세포독소 b 서브유닛 돌연변이체 - Google Patents

서브틸라제 세포독소 b 서브유닛 돌연변이체 Download PDF

Info

Publication number
KR102703633B1
KR102703633B1 KR1020197014900A KR20197014900A KR102703633B1 KR 102703633 B1 KR102703633 B1 KR 102703633B1 KR 1020197014900 A KR1020197014900 A KR 1020197014900A KR 20197014900 A KR20197014900 A KR 20197014900A KR 102703633 B1 KR102703633 B1 KR 102703633B1
Authority
KR
South Korea
Prior art keywords
linked
glycolylneuraminic acid
acid
protein
subb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197014900A
Other languages
English (en)
Korean (ko)
Other versions
KR20190084995A (ko
Inventor
마이클 폴 제닝스
크리스토퍼 데이
애드리엔 웹스터 페이턴
제임스 클리랜드 페이턴
Original Assignee
그리피스 유니버시티
더 유니버시티 오브 아델라이드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904572A external-priority patent/AU2016904572A0/en
Application filed by 그리피스 유니버시티, 더 유니버시티 오브 아델라이드 filed Critical 그리피스 유니버시티
Publication of KR20190084995A publication Critical patent/KR20190084995A/ko
Application granted granted Critical
Publication of KR102703633B1 publication Critical patent/KR102703633B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
KR1020197014900A 2016-11-09 2017-11-09 서브틸라제 세포독소 b 서브유닛 돌연변이체 Active KR102703633B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016904572 2016-11-09
AU2016904572A AU2016904572A0 (en) 2016-11-09 Subtilase cytotoxin b subunit mutant
PCT/AU2017/051230 WO2018085888A1 (en) 2016-11-09 2017-11-09 Subtilase cytotoxin b subunit mutant

Publications (2)

Publication Number Publication Date
KR20190084995A KR20190084995A (ko) 2019-07-17
KR102703633B1 true KR102703633B1 (ko) 2024-09-05

Family

ID=62109062

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197014900A Active KR102703633B1 (ko) 2016-11-09 2017-11-09 서브틸라제 세포독소 b 서브유닛 돌연변이체

Country Status (9)

Country Link
US (2) US11371033B2 (enExample)
EP (1) EP3538544B1 (enExample)
JP (1) JP7123921B2 (enExample)
KR (1) KR102703633B1 (enExample)
CN (1) CN110402251A (enExample)
AU (1) AU2017358401B2 (enExample)
CA (1) CA3044303A1 (enExample)
ES (1) ES2983352T3 (enExample)
WO (1) WO2018085888A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112760305B (zh) * 2021-01-25 2022-04-29 浙江工业大学 一种栖热腔菌磷酸酶突变体及其应用
WO2022232886A1 (en) * 2021-05-06 2022-11-10 Inoviq Limited Methods relating to tumour-derived extracellular vesicles
US20240239846A1 (en) * 2021-05-14 2024-07-18 The University Of Adelaide Methods of analysing a sample

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP1386927B1 (en) * 2002-08-02 2005-03-30 Institut Curie Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors
CA2465009C (en) 2003-12-22 2015-02-03 Adelaide Research & Innovation Pty Ltd. Cytotoxin with a subtilase domain
JP2014505064A (ja) * 2011-01-26 2014-02-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Exp. Med., Vol. 200, pp. 35-46 (2004)

Also Published As

Publication number Publication date
US11371033B2 (en) 2022-06-28
CA3044303A1 (en) 2018-05-17
JP2020501521A (ja) 2020-01-23
US20190367895A1 (en) 2019-12-05
CN110402251A (zh) 2019-11-01
EP3538544A1 (en) 2019-09-18
EP3538544B1 (en) 2024-03-27
JP7123921B2 (ja) 2022-08-23
US20220372459A1 (en) 2022-11-24
AU2017358401A1 (en) 2019-05-30
ES2983352T3 (es) 2024-10-22
WO2018085888A1 (en) 2018-05-17
KR20190084995A (ko) 2019-07-17
EP3538544A4 (en) 2020-04-15
AU2017358401B2 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
JP7479435B2 (ja) 癌治療および判断ターゲットとしてのｌｙ７５
ES2951674T3 (es) Anticuerpo anti-MUC1
KR101523705B1 (ko) Ｓｐａｒｃ 결합 ｓｃｆｖｓ
KR102005562B1 (ko) 메디토프를 위한 단일클론 항체 프레임워크 결합 계면, 메디토프 전달 시스템 및 이의 사용 방법
USRE50282E1 (en) Specific modification of antibody with IgG-binding peptide
CN109563503B (zh) 抗b7-h4抗体
US8591893B2 (en) Paratope and epitope of anti-mortalin antibody
KR20150119164A (ko) Dll3 결합 시약을 포함하는 암에 대한 치료적 및 진단적 타겟
EA031698B1 (ru) Человеческие анти-тау антитела
US20220372459A1 (en) Subtilase cytotoxin b subunit mutant
KR102014383B1 (ko) G 단백질 연결 수용체의 활성 조절 인간 항체
EP2985295A1 (en) Antibodies specific for MMP9
KR101734931B1 (ko) 아르기닌화된 ｅｒ 단백질에 특이적으로 결합하는 항체 및 이의 용도
CN114269791B (zh) 用于治疗体液免疫抑制疾病的体液免疫抑制拮抗剂的组合物和用途
Wang et al. Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis
KR20150131655A (ko) Aimp2-dx2-34s 단백질 및 이의 제조방법
WO2000052470A1 (fr) Moyen de diagnostic et de traitement de la leucemie

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190523

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201105

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230613

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230613

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20240227

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20231013

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20230113

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201105

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240621

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240528

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20240227

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20231013

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230113

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201105

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240902

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240903

End annual number: 3

Start annual number: 1

PG1601 Publication of registration